ADIL - エ―ダイヤル・ファ―マシュ―ティカルズ (Adial Pharmaceuticals Inc) エ―ダイヤル・ファ―マシュ―ティカルズ

 ADILのチャート


 ADILの企業情報

symbol ADIL
会社名 ADial Pharmaceuticals Inc (エ―ダイヤル・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a therapeutic agent for the treatment of alcohol use disorder (AUD). Its lead drug product is AD04. AD04 is a selective serotonin-3 antagonist. AD04 can also be used for the treatment of other addictive disorders such as obesity smoking and drug addiction. The Company has completed a Phase-II clinical trials of AD04.   エ―ダイヤル・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、アルコ―ル依存症などアルコ―ルの使用障害に対する治療薬の開発に従事する。同社の主力製品に、吐き気や嘔吐の治療に有効な選択的セトロニン3拮抗薬である「AD04」を含む。本社所在地はバ―ジニア州シャ―ロッツビル。   Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity.
本社所在地 1180 Seminole Trail Suite 495 Charlottesville VA 22902 USA
代表者氏名
代表者役職名
電話番号 +1 434-422-9800
設立年月日 40483
市場名 NASDAQ Small Cap
ipoyear 2018年
従業員数
url www.adialpharma.com
nasdaq_url https://www.nasdaq.com/symbol/adil
adr_tso
EBITDA EBITDA(百万ドル) -2.66463
終値(lastsale) 2.72
時価総額(marketcap) 17783969.28
時価総額 時価総額(百万ドル) 19.40650
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 20.25449
当期純利益 当期純利益(百万ドル) -2.86793
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Adial Pharmaceuticals Inc revenues was not reported. Net loss increased from $443K to $2.2M. Higher net loss reflects General and Administrative Expenses increase of 35% to $417K (expense) Interest Expense increase from $32K to $103K (expense) Research and development expenses increase of 29% to $132K (expense).

 ADILのテクニカル分析


 ADILのニュース

   Adial Pharmaceuticals Inc. (NASDAQ:ADIL) Is Currently -213.58% Below Its 52-Week High, But Upside Potential Is Still There.  2022/04/09 13:00:00 Marketing Sentinel
In last trading session, Adial Pharmaceuticals Inc. (NASDAQ:ADIL) saw 0.52 million shares changing hands with its beta currently measuring 0.61. Company’s recent per share price level of $1.62 trading at -$0.2 or -10.99% at ring of the bell on the day assigns it a market valuation of $38.07M. That closing price of ADIL’s stock is … Adial Pharmaceuticals Inc. (NASDAQ:ADIL) Is Currently -213.58% Below Its 52-Week High, But Upside Potential Is Still There. Read More »
   Adial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th  2022/03/22 13:15:00 GlobeNewswire
CHARLOTTESVILLE, Va., March 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Adial’s Chief Executive Officer will participate in a fireside chat at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, being held virtually on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT. Those who wish to attend the conference must first sign up to become an M-Vest member.
   Adial Pharmaceuticals announces $10M registered direct offering  2022/02/11 14:07:01 Seeking Alpha
Adial Pharmaceuticals (ADIL) will sell 4.2M shares to a single institutional investor worth ~$10M in a registered direct offering and issue warrants in a concurrent private…
   Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate''s PNV-5032 as a Potential Treatment for Asthma  2022/02/09 14:25:00 Benzinga
CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL , ADILW)) ("Adial" or the "Company") , today announced positive in vivo data for PNV-5032, as a potential treatment for asthma. PNV-5032 demonstrated a significant inhibition of pulmonary flow resistance, which is a measure of asthmatic response, in an in vivo model. PNV-5032 Relevant Information Greater than 1000-fold selective over the adenosine A1 receptor in potency assays Demonstrated solubility more than 100 times greater than other selective adenosine compounds of the same class currently known to the Company Solubility of an inhaled product allows dissolution in the aerosolized mist for fine distribution over the bronchioles and can be important in facilitating bronchiole membrane penetration Findings indicate drug development potential of molecules of this class, possibly to treat asthma Covered by a composition of matter patent application for patent protection through 2042 with expected statutory extension to 2047 Study Design Sheep, which respond to allergens and adenosine challenges in a manner similar to humans, were initially challenged with an aerosolized dose of Ascaris Sum allergens.
   Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovates PNV-5032 as a Potential Treatment for Asthma  2022/02/09 14:25:00 GlobeNewswire
CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company) , today announced positive in vivo data for PNV-5032, as a potential treatment for asthma. PNV-5032 demonstrated a significant inhibition of pulmonary flow resistance, which is a measure of asthmatic response, in an in vivo model.
   Adial Pharmaceuticals inks research collaboration agreement with University of Virginia  2021/09/28 14:07:38 Seeking Alpha
   Adial Pharmaceuticals Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound Healing  2021/09/28 13:49:00 Intrado Digital Media
Collaboration targeting development of new adenosine formulations that can be absorbed transdermally Collaboration targeting development of new adenosine formulations that can be absorbed transdermally
   Adial CEO William Stilley Invited to Participate in Maxim Group''s Virtual Panel Series Conference: "Disruptors in the Mental Health Space"  2021/09/15 14:07:50 Benzinga
CHARLOTTESVILLE, Va., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL , ADILW)) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals, has been invited to participate in Maxim Group''s virtual panel series conference: "Disruptors in the Mental Health Space," which will be taking place on Wednesday, September 22, 2021 from 9:00am-3:00pm ET. The conference will consist of a series of roundtable panel discussions that will include speakers from both psychedelic, and non-psychedelic, focused companies. Leading and moderating the panel discussions will be Maxim''s Biotechnology Full story available on Benzinga.com
   Adial CEO William Stilley Invited to Participate in Maxim Group’s Virtual Panel Series Conference: “Disruptors in the Mental Health Space”  2021/09/15 14:07:00 Intrado Digital Media
CHARLOTTESVILLE, Va., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals, has been invited to participate in Maxim Group’s virtual panel series conference: "Disruptors in the Mental Health Space," which will be taking place on Wednesday, September 22, 2021 from 9:00am-3:00pm ET.
   The Daily Biotech Pulse: MacroGenics'' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA''s FDA Nod  2021/09/08 11:32:07 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Candel Therapeutics, Inc. (NASDAQ: CADL ) (announced completion of patient enrollment in the pivotal phase 3 study of CAN-2409 in prostate cancer) Cardiol Therapeutics Inc. (NASDAQ: CRDL ) (announced addition to its board) Caribou Biosciences, Inc. (NASDAQ: CRBU ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) Edwards Lifesciences Corporation (NYSE: EW ) Erasca, Inc. (NASDAQ: ERAS ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Imago BioSciences, Inc. (NASDAQ: IMGO ) INmune Bio, Inc. (NASDAQ: INMB ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Lyell Immunopharma, Inc. (NASDAQ: LYEL ) Medpace Holdings, Inc. (NASDAQ: MEDP ) MiMedx Group, Inc. (NASDAQ: MDXG ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Nuvalent, Inc. (NASDAQ: NUVL ) PAVmed Inc. (NASDAQ: PAVM ) Protagonist Therapeutics, Inc. (NASDAQ: PTGX ) (reacted to an executive appointment) Psychemedics Corporation (NASDAQ: PMD ) Quest Diagnostics Incorporated (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) Repligen Corporation (NASDAQ: RGEN ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Surrozen, Inc. (NASDAQ: SRZN ) ( reacted to positive analyst action) Syneos Health, Inc. (NASDAQ: SYNH ) Tandem Diabetes Care, Inc. (NASDAQ: TNDM ) (reacted to the news of inclusion of the stock to the S&P MidCap 400 Index) Tango Therapeutics, Inc. (NASDAQ: TNGX ) Verve Therapeutics, Inc. (NASDAQ: VERV ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps No NYSE- or Nasdaq-listed stock hit 52-week lows Tuesday.
   The Daily Biotech Pulse: MacroGenics'' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA''s FDA Nod  2021/09/08 11:32:07 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Candel Therapeutics, Inc. (NASDAQ: CADL ) (announced completion of patient enrollment in the pivotal phase 3 study of CAN-2409 in prostate cancer) Cardiol Therapeutics Inc. (NASDAQ: CRDL ) (announced addition to its board) Caribou Biosciences, Inc. (NASDAQ: CRBU ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) Edwards Lifesciences Corporation (NYSE: EW ) Erasca, Inc. (NASDAQ: ERAS ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Imago BioSciences, Inc. (NASDAQ: IMGO ) INmune Bio, Inc. (NASDAQ: INMB ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Lyell Immunopharma, Inc. (NASDAQ: LYEL ) Medpace Holdings, Inc. (NASDAQ: MEDP ) MiMedx Group, Inc. (NASDAQ: MDXG ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Nuvalent, Inc. (NASDAQ: NUVL ) PAVmed Inc. (NASDAQ: PAVM ) Protagonist Therapeutics, Inc. (NASDAQ: PTGX ) (reacted to an executive appointment) Psychemedics Corporation (NASDAQ: PMD ) Quest Diagnostics Incorporated (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) Repligen Corporation (NASDAQ: RGEN ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Surrozen, Inc. (NASDAQ: SRZN ) ( reacted to positive analyst action) Syneos Health, Inc. (NASDAQ: SYNH ) Tandem Diabetes Care, Inc. (NASDAQ: TNDM ) (reacted to the news of inclusion of the stock to the S&P MidCap 400 Index) Tango Therapeutics, Inc. (NASDAQ: TNGX ) Verve Therapeutics, Inc. (NASDAQ: VERV ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps No NYSE- or Nasdaq-listed stock hit 52-week lows Tuesday.
   Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference  2021/09/07 13:00:00 Intrado Digital Media
CHARLOTTESVILLE, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals, will be presenting at the H.C. Wainwright 23 rd Annual Global Investment Conference being held virtually between September 13-15, 2021.
   Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder  2021/08/31 13:30:00 Wallstreet:Online
ONWARD trial enrollment closed; trial completion expected in Q1 2022 CHARLOTTESVILLE, Va., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces it has successfully enrolled 302
   Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder  2021/08/31 13:30:00 Intrado Digital Media
ONWARD trial enrollment closed; trial completion expected in Q1 2022 ONWARD trial enrollment closed; trial completion expected in Q1 2022
   Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder  2021/08/20 14:45:00 Intrado Digital Media
On track for trial completion in the first quarter of 2022

 関連キーワード  (医薬品 米国株 エ―ダイヤル・ファ―マシュ―ティカルズ ADIL Adial Pharmaceuticals Inc)

 twitter  (公式ツイッターやCEOツイッターなど)